The week in health tech, explained in plain English.Get the free newsletter →
August 8, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Crystalys Raises $130M for Gout Drug Dotinurad

Crystalys Therapeutics has added $130 million in new financing to push its gout drug dotinurad through pivotal testing, MedCity News reports. Dotinurad is a URAT1 inhibitor, a class designed to help the body clear uric acid, the buildup of which drives the painful inflammation of gout.

Gout is one of the most common inflammatory conditions, yet treatment options remain limited and many patients fail to reach target uric acid levels on existing therapies. That gap is drawing fresh capital and dealmaking. Dotinurad works through the same mechanism as a molecule Sobi brought into its pipeline via a roughly $950 million acquisition, according to MedCity News, underscoring how large pharma is betting on the same target.

For Crystalys, the raise funds the expensive, late-stage trials needed to prove efficacy and safety before any regulatory filing. For the broader field, the money signals that investors see commercial upside in a prevalent, undertreated disease that has long lacked innovation.

More in Finance

Finance

CMS Finalizes 2.3% FY2027 Pay Bumps for Rehab, Hospices

CMS finalized fiscal 2027 payment rules giving inpatient rehabilitation facilities and hospices each a 2.3% payment increase.

Why it matters: Thin Medicare increases set the revenue baseline for rehab and hospice operators already squeezed by labor and supply costs.

Finance

Hospital Margins Slip 5% as Profitability Divide Widens

Hospital operating margins fell 5% nationally in early 2026, deepening a profitability divide between smaller hospitals and large nonprofit systems.

Why it matters: A widening margin gap determines which hospitals can invest, consolidate, or survive, reshaping access and competition across the industry.

Finance

Hospital CFOs Look Past Cost Cuts to Grow Margins

Health system CFOs are shifting from cost-cutting to revenue integrity, payer negotiation and AI-assisted reporting to sustain margins, per Becker's.

Why it matters: Hospital margins remain thin, and where CFOs invest next shapes which vendors, technologies and strategies win healthcare dollars.